NEWS April 8, 2009 – Raptiva RECALL – The makers of the psoriasis drug Raptiva, Genentech Inc, has stated that they will pull the drug off the market. Raptiva has been recalled due to linked to an increased risk of progressive multifocal leukoencephalopathy (PML), a rare and usually fatal disease of the central nervous system.

Raptiva is approved for the treatment of chronic moderate-to-severe plaque psoriasis in adults 18 years or older who are candidates for systemic therapy or light therapy.

Genentech Inc., said Raptiva will not be available after June 8 and estimated that around 2,000 U.S. patients may be receiving the drug for chronic plaque psoriasis.

If you or a loved one has been harmed or injured from Raptiva please contact a Raptiva Lawyer

http://www.resource4thepeople.com/defectivedrugs/raptiva.html